1 Min Read
Oct 23 (Reuters) - GlaxoSmithKline Plc : * CEO says research and development costs coming down as expensive studies come
to end * CEO says controlled research and development cost trend likely to continue in
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.